UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Velcade
DRUG: Melphalan
DRUG: Thalidomide
DRUG: Dexamethasone
DRUG: Cisplatin
DRUG: Adriamycin
DRUG: Cyclophosphamide
DRUG: Etoposide

Sponsor

University of Arkansas